Loading…
SCREEN for Type 1 Diabetes Act of 2026
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2026 · third_quarter · Health Issues
H.R. 10227, the INSULIN Act and Issues pertaining to FDA modernization; S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to grant funding for the Special Diabetes Program; Issues pertaining to pending legislation for reclassification of deceased donor islet cells.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $150,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · third_quarter · Health Issues
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Client expense: Not reported · Firm income: $40,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Client expense: Not reported · Firm income: $80,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act S. 4612 SCREEN for Type 1 Diabetes Act Newborn Screening Amendment to NDAA
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE